Observational studyScientific reports2026
Evaluating the correlation between fecal and serum calprotectin in inflammatory bowel disease.
Observational study in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), require accurate assessment of inflammatory activity to guide treatment and monitor disease course. While fecal calprotectin (FC) is an established non-invasive biomarker of intestinal inflammation, serum calprotectin (sC) has been proposed as a more convenient systemic marker, though its relationship to FC remains unclear. We conducted a prospective observational cohort study in 426 patients with IBD (277 CD, 149 UC). Both stool and blood samples were analyzed using the QUANTA Flash® Calprotectin chemiluminescent immunoassay. Overall, the correlation between fCal and sCal was weak (Spearman’s ρ = 0.21), with substantial proportional bias and wide limits of agreement, indicating poor concordance between the two biomarkers. No significant association was observed at low or intermediate fCal concentrations, while a moderate correlation emerged only at fCal levels > 250 µg/g, although systematic bias and heteroscedasticity persisted. fCal correlated more closely with symptom-based disease activity in ulcerative colitis, whereas sCal showed only weak associations with clinical indices, particularly in Crohn’s disease. Both biomarkers demonstrated modest but significant correlations with C-Reactive Protein, reflecting overlapping but distinct inflammatory pathways. In conclusion, serum calprotectin cannot be considered a surrogate for fecal calprotectin in assessing intestinal inflammation in IBD. However, it may provide complementary information on systemic inflammatory activity at higher disease burden, while fecal calprotectin remains the gold-standard noninvasive marker of mucosal inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.